STOCK TITAN
  1. Home
  2. Sec-filings
  3. VCYT
  4. [Form 4] VERACYTE, INC. Insider Trading Activity

VCYT officer sold 8,349 shares at $36.02 via 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.

Positive

  • Sale executed under a Rule 10b5-1 plan adopted 09/04/2024, indicating pre-scheduled trading
  • Filing discloses price range ($35.82 to $36.28) and weighted average ($36.0174), providing transparency

Negative

  • Insider reduced holdings by 8,349 shares, lowering beneficial ownership to 92,441 shares
  • Concentrated sale size could be viewed as a notable distribution of insider stock in the near term

Insights

Insider sale executed under a pre-existing 10b5-1 plan; holdings fell to 92,441 shares.

The reporting person, the company's Chief Scientific & Medical Officer, executed a block sale of 8,349 shares on 10/06/2025 at a weighted average price of $36.0174. The filing explicitly links the trades to a Rule 10b5-1 plan adopted on 09/04/2024, which provides an affirmative defense for scheduled insider transactions.

The main dependency for interpreting intent is the 10b5-1 plan timing and structure; because the plan date is disclosed, the sale is documented as pre-planned rather than opportunistic. Investors may note the remaining beneficial ownership of 92,441 shares as a continuing stake to monitor over the next 6–12 months for further scheduled transactions or changes.

Insider Febbo Phillip G.
Role Chief Scientific & Med Officer
Sold 8,349 shs ($301K)
Type Security Shares Price Value
Sale Common Stock 8,349 $36.0174 $301K
Holdings After Transaction: Common Stock — 92,441 shares (Direct)
Footnotes (1)
  1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. Represents weighted average sales price. Sale prices for the transactions range from $35.82 to $36.28. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Febbo Phillip G.
(Last) (First) (Middle)
6000 SHORELINE COURT, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific & Med Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S(1) 8,349 D $36.0174(2) 92,441 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024.
2. Represents weighted average sales price. Sale prices for the transactions range from $35.82 to $36.28. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Veracyte (VCYT) insider Phillip Febbo sell?

Phillip Febbo sold 8,349 shares of Veracyte common stock on 10/06/2025.

At what price were the VCYT shares sold?

The weighted average sale price was $36.0174, with individual sale prices ranging from $35.82 to $36.28.

Was the sale part of a pre-arranged plan?

Yes. The transactions were made pursuant to a Rule 10b5-1 plan adopted on 09/04/2024.

How many VCYT shares does the reporting person own after the sale?

After the reported sales, the reporting person beneficially owned 92,441 shares.

Were any derivative or option transactions reported?

No. The Form 4 reports only non-derivative common stock sales and shows no derivative securities transactions.